Vizora日本語

Kobayashi PharmaceuticalKOBAYASHI PHARMACEUTICAL CO.,LTD.4967東証プライム化学FY ending Dec 2025, consolidated, J-GAAP

Kobayashi Pharmaceutical FY ending Dec 2019 results

About 78% of Kobayashi Pharmaceutical's sales come from Domestic Business, with International Business and Direct Marketing Business making up much of the rest.

Out of every ¥100 of sales, about ¥16 is left as operating profit.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Kobayashi Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Dec 2019
Cost of sales
¥43
SG&A
¥41
Operating profit
¥16
Net profit kept
¥12

Margin funnel (derived from reported values)Gross margin 57.5% → Operating margin 16.2% → Net margin 12.1%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2019

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第106期(2023/01/01－2023/12/31)

    ID S100T3KX2024-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第104期(令和3年1月1日－令和3年12月31日)

    ID S100NR6F2022-03-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第103期(令和2年1月1日－令和2年12月31日)

    ID S100L0OB2021-03-26Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image